Diagnostic test based on urinary tumor markers hold promise for earlier or prompt detection of bladder cancer in patients ...
Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...
Stocktwits on MSN
IBRX stock is back: Anktiva now targets severe pneumonia after clearing key checkpoint in bladder cancer trial
The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...
Khaberni - A number of researchers from the College of Medicine at Stanford University, Columbia University, and Beaumont ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS ...
Everyday Health on MSN
8 treatments for metastatic bladder cancer pain
Bladder cancer can cause pain when it spreads to different areas of the body. From NSAIDs to nerve blocks, here are the ...
A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results